• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

VaxArray immunogenicity study published in Vaccine

Bioengineer by Bioengineer
April 26, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: InDevR, Inc.

BOULDER COLORADO (4/25/18) — "VaxArray for Hemagglutinin and Neuraminidase Potency Testing of Influenza Vaccines" describes a study designed to test the relationship between VaxArray-measured potency and vaccine-induced immunogenicity in mice. The study results represent a milestone in an industry-wide effort to qualify new potency assays for influenza vaccines.

For an A/H3N2 vaccine, the VaxArray neuraminidase (NA) potency assay was strongly correlated with enzymatic activity, highly sensitive to immunogenic forms of NA, and correlated with serum levels of NA inhibiting antibodies. In addition, the VaxArray hemagglutinin (HA) potency assay demonstrated equivalency to the current gold standard method and confirms the expected relationship to immunogenicity.

Although the authors acknowledge that more testing is needed, the consistent and predictive immunogenicity-potency relationships observed for VaxArray HA and NA support a conclusion that these assays can serve as a proxy for vaccine-induced immunogenicity and thereby are a measure the potency of the targeted antigen.

###

The effort was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Human Services (HHS), under Contract Number HHSN272201200005I. Additional resource support for serologic testing was provided by CBER FDA.

Find more information about the entire VaxArray vaccine potency testing platform at: https://indevr.com/products/vaxarray/

About InDevR

InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing diagnostics, vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit http://www.indevr.com or call 303-402-9100.

About Vaccine

Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society and The Japanese Society for Vaccinology and is published by Elsevier http://www.elsevier.com/locate/vaccine

HHS is not responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government or HHS.

MEDIA CONTACT
Shannon Rodriguez
InDevR
+1-303-402-9100
[email protected]

Media Contact

Shannon Rodriguez
[email protected]
303-402-9100

Home

Related Journal Article

http://dx.doi.org/10.1016/j.vaccine.2018.04.048

Share13Tweet8Share2ShareShareShare2

Related Posts

Boosting Remote Healthcare: Stepped-Wedge Trial Insights

February 7, 2026

Barriers and Boosters of Seniors’ Physical Activity in Karachi

February 7, 2026

Evaluating Pediatric Emergency Care Quality in Ethiopia

February 7, 2026

TPMT Expression Predictions Linked to Azathioprine Side Effects

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosting Remote Healthcare: Stepped-Wedge Trial Insights

Barriers and Boosters of Seniors’ Physical Activity in Karachi

Evaluating Pediatric Emergency Care Quality in Ethiopia

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.